3-Arylindole or 3-arylindazole derivatives having formula (see formula I) wherein Ar is optionally substituted phenyl or a heteroaromatic group; R1-R4 are independently selected from hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro, alkylthio, alkylsulphonyl, alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoromethylthio; the dotted lines designate optional bonds; X is N or a group CR6 wherein R6 is hydrogen, halogen, trifluoromethyl or alkyl, or X is CH2; Y is N or CH, or Y is C; R5 is hydrogen, cycloalkyl, cycloalkylmethyl, alkyl or alkenyl, optionally substituted with one or two hydroxy groups, or R5 is a group taken from structures 1a an d 1b: (see formula 1a, 1b) wherein n is an integer from 2 - 6; W is O or S; U is N or CH ; Z is -(CH2)m -, m being 2 or 3 , -CH=CH-, 1,2-phenylene or -COCH2- or -CSCH2-; V is O, S, CH2, or NR7; U1 is O, S, CH2 or NR8; and V1 is NR9R10, OR11, SR12 or CR13R14R15, and R7- R15 are independently hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylalky l; may be prepared by methods known per se. The compounds are selective central ly acting 5-HT2-antagonists in the brain and are useful in treatment of anxiety , agression, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, drug-induces Parkinsonism and Parkinson's disease.
3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES